Demographic characteristics of patients undergoing autologous hematopoietic-cell transplantation for hematologic malignancies and surviving at least 2 years
. | . | Primary diagnoses . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| Variables . | Entire cohort . | AML . | ALL . | NHL . | HD . | |||
| Total no. of patients | 854 | 158 | 59 | 392 | 245 | |||
| Median age at HCT, y (range) | 36.5 (0.6-69.1) | 34.8 (0.6-62.9) | 11.1 (2.5-55.7) | 43.7 (2.0-69.1) | 30.5 (7.2-56.9) | |||
| Age at HCT, y (%) | ||||||||
| Less than 18 | 91 (10.7) | 28 (17.7) | 36 (61.0) | 9 (2.3) | 18 (7.3) | |||
| 18 to 45 | 505 (59.1) | 75 (47.5) | 21 (35.6) | 209 (53.3) | 200 (81.6) | |||
| More than 45 | 258 (30.2) | 55 (34.8) | 2 (3.4) | 174 (44.4) | 27 (11.1) | |||
| Sex: male (%) | 506 (59.3) | 88 (55.7) | 47 (79.7) | 230 (58.7) | 141 (57.6) | |||
| Source of stem cells, no. (%) | ||||||||
| Bone marrow | 269 (31.5) | 69 (43.7) | 55 (93.2) | 81 (20.7) | 64 (26.1) | |||
| Peripheral blood stem cells | 456 (53.4) | 62 (39.2) | 3 (5.1) | 259 (66.1) | 132 (53.9) | |||
| BM + PBSCs | 129 (15.1) | 27 (17.1) | 1 (1.7) | 52 (13.2) | 49 (20.0) | |||
| Race/ethnicity, no. (%) | ||||||||
| White | 692 (81) | 122 (77) | 48 (81) | 321 (82) | 201 (82) | |||
| Hispanic | 104 (12.2) | 23 (15) | 5 (8) | 46 (12) | 30 (12) | |||
| Other | 58 (6.8) | 13 (8) | 6 (10) | 25 (6) | 14 (6) | |||
| Year of HCT (%) | ||||||||
| 1980 to 1989 | 167 (19.5) | 23 (14.6) | 40 (67.7) | 49 (12.5) | 0 (22.4) | |||
| 1990 to 1994 | 351 (41.1) | 67 (42.4) | 14 (23.7) | 170 (43.3) | 100 (40.8) | |||
| 1995 to 1999 | 336 (39.3) | 68 (43.0) | 5 (8.5) | 173 (44.1) | 90 (36.7) | |||
| Years since HCT (range) | 7.6 (2.0-20.5) | 8.3 (2.3-16.8) | 10.3 (2.0-20.5) | 7.3 (2.0-18.4) | 7 (2.0-18.1) | |||
| Conditioning regimen (%) | ||||||||
| Total body irradiation | 575 (67.6) | 124 (79.5) | 58 (98.3) | 314 (80.3) | 79 (32.2) | |||
| Cyclophosphamide | 828 (97.3) | 152 (97.4) | 45 (76.3) | 386 (98.7) | 245 (100) | |||
| Busulfan | 33 (3.9) | 32 (20.5) | 1 (1.7) | 0 (0) | 0 (0) | |||
| Etoposide | 635 (74.6) | 100 (64.1) | 6 (10.2) | 286 (73.1) | 243 (99.2) | |||
| Carmustine | 234 (27.5) | 0 (0) | 0 (0) | 71 (18.2) | 163 (66.5) | |||
| Disease status at HCT (%) | ||||||||
| Standard risk | 498 (58.5) | 153 (96.8) | 48 (81.4) | 219 (55.9) | 78 (32.1) | |||
| High risk | 354 (41.5) | 5 (3.2) | 11 (18.6) | 173 (44.1) | 165 (67.9) | |||
| Institution (%) | ||||||||
| City of Hope | 553 (64.8) | 103 (65.2) | 6 (10.2) | 277 (70.7) | 167 (68.2) | |||
| University of Minnesota | 301 (35.2) | 55 (34.8) | 53 (89.8) | 115 (29.3) | 78 (31.8) | |||
| No. of late deaths (%) | 251 (29.4) | 24 (15.2) | 24 (40.7) | 113 (28.8) | 90 (36.7) | |||
| 2 to 5 y after HCT | 192 (76.5) | 16 (66.7) | 19 (79.2) | 84 (74.3) | 73 (81.1) | |||
| 6 to 10 y after HCT | 51 (20.3) | 7 (29.2) | 4 (16.7) | 25 (22.1) | 15 (16.7) | |||
| 11 to 15 y after HCT | 8 (3.2) | 1 (4.2) | 1 (4.2) | 4 (3.5) | 2 (2.2) | |||
| Age at death, y (range) | 42.5 (5.4-72.7) | 46.9 (5.5-66.2) | 19.6 (5.4-44.2) | 51.5 (13.7-72.7) | 36.1 (16.1-58.9) | |||
. | . | Primary diagnoses . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| Variables . | Entire cohort . | AML . | ALL . | NHL . | HD . | |||
| Total no. of patients | 854 | 158 | 59 | 392 | 245 | |||
| Median age at HCT, y (range) | 36.5 (0.6-69.1) | 34.8 (0.6-62.9) | 11.1 (2.5-55.7) | 43.7 (2.0-69.1) | 30.5 (7.2-56.9) | |||
| Age at HCT, y (%) | ||||||||
| Less than 18 | 91 (10.7) | 28 (17.7) | 36 (61.0) | 9 (2.3) | 18 (7.3) | |||
| 18 to 45 | 505 (59.1) | 75 (47.5) | 21 (35.6) | 209 (53.3) | 200 (81.6) | |||
| More than 45 | 258 (30.2) | 55 (34.8) | 2 (3.4) | 174 (44.4) | 27 (11.1) | |||
| Sex: male (%) | 506 (59.3) | 88 (55.7) | 47 (79.7) | 230 (58.7) | 141 (57.6) | |||
| Source of stem cells, no. (%) | ||||||||
| Bone marrow | 269 (31.5) | 69 (43.7) | 55 (93.2) | 81 (20.7) | 64 (26.1) | |||
| Peripheral blood stem cells | 456 (53.4) | 62 (39.2) | 3 (5.1) | 259 (66.1) | 132 (53.9) | |||
| BM + PBSCs | 129 (15.1) | 27 (17.1) | 1 (1.7) | 52 (13.2) | 49 (20.0) | |||
| Race/ethnicity, no. (%) | ||||||||
| White | 692 (81) | 122 (77) | 48 (81) | 321 (82) | 201 (82) | |||
| Hispanic | 104 (12.2) | 23 (15) | 5 (8) | 46 (12) | 30 (12) | |||
| Other | 58 (6.8) | 13 (8) | 6 (10) | 25 (6) | 14 (6) | |||
| Year of HCT (%) | ||||||||
| 1980 to 1989 | 167 (19.5) | 23 (14.6) | 40 (67.7) | 49 (12.5) | 0 (22.4) | |||
| 1990 to 1994 | 351 (41.1) | 67 (42.4) | 14 (23.7) | 170 (43.3) | 100 (40.8) | |||
| 1995 to 1999 | 336 (39.3) | 68 (43.0) | 5 (8.5) | 173 (44.1) | 90 (36.7) | |||
| Years since HCT (range) | 7.6 (2.0-20.5) | 8.3 (2.3-16.8) | 10.3 (2.0-20.5) | 7.3 (2.0-18.4) | 7 (2.0-18.1) | |||
| Conditioning regimen (%) | ||||||||
| Total body irradiation | 575 (67.6) | 124 (79.5) | 58 (98.3) | 314 (80.3) | 79 (32.2) | |||
| Cyclophosphamide | 828 (97.3) | 152 (97.4) | 45 (76.3) | 386 (98.7) | 245 (100) | |||
| Busulfan | 33 (3.9) | 32 (20.5) | 1 (1.7) | 0 (0) | 0 (0) | |||
| Etoposide | 635 (74.6) | 100 (64.1) | 6 (10.2) | 286 (73.1) | 243 (99.2) | |||
| Carmustine | 234 (27.5) | 0 (0) | 0 (0) | 71 (18.2) | 163 (66.5) | |||
| Disease status at HCT (%) | ||||||||
| Standard risk | 498 (58.5) | 153 (96.8) | 48 (81.4) | 219 (55.9) | 78 (32.1) | |||
| High risk | 354 (41.5) | 5 (3.2) | 11 (18.6) | 173 (44.1) | 165 (67.9) | |||
| Institution (%) | ||||||||
| City of Hope | 553 (64.8) | 103 (65.2) | 6 (10.2) | 277 (70.7) | 167 (68.2) | |||
| University of Minnesota | 301 (35.2) | 55 (34.8) | 53 (89.8) | 115 (29.3) | 78 (31.8) | |||
| No. of late deaths (%) | 251 (29.4) | 24 (15.2) | 24 (40.7) | 113 (28.8) | 90 (36.7) | |||
| 2 to 5 y after HCT | 192 (76.5) | 16 (66.7) | 19 (79.2) | 84 (74.3) | 73 (81.1) | |||
| 6 to 10 y after HCT | 51 (20.3) | 7 (29.2) | 4 (16.7) | 25 (22.1) | 15 (16.7) | |||
| 11 to 15 y after HCT | 8 (3.2) | 1 (4.2) | 1 (4.2) | 4 (3.5) | 2 (2.2) | |||
| Age at death, y (range) | 42.5 (5.4-72.7) | 46.9 (5.5-66.2) | 19.6 (5.4-44.2) | 51.5 (13.7-72.7) | 36.1 (16.1-58.9) | |||
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; BM, bone marrow; PBSCs, peripheral blood stem cells.